DSpace@İnönü

Yazar "Dagdelen, S" için listeleme

Yazar "Dagdelen, S" için listeleme

Sırala: Sıra: Sonuçlar:

  • VOLATILE COMPOSITION, ANTIOXIDANT AND ANTIMICROBIAL ACTIVITIES OF HERBAL 
    Dagdelen, S; Bilenler, T; Durmaz, G; Gokbulut, I; Hayaloglu, AA; Karabulut, I (2014)
    The aim of this study was to investigate the antioxidative, antimicrobial and aroma characteristics of the most popular herbs, with local, namely Sirmo (Allium schoenoprasum [Liliaceae]), Mendi (Chaerophyllum macropodum ...
  • Clinical outcomes of non-diabetic COVID-19 patients with different blood 
    Haymana, C; Demirci, I; Tasci, I; Cakal, E; Salman, S; Ertugrul, D; Ata, N; Unluturk, U; Dagdelen, S; Atmaca, A; Sahin, M; Celik, O; Demir, T; Emral, R; Sahin, I; Caglayan, M; Satman, I; Sonmez, A (2021)
    Purpose New coronavirus disease 2019 (COVID-19) has a worse prognosis in patients with diabetes. However, there are insufficient data about the effect of hyperglycemia on COVID-19 prognosis in non-diabetic patients. This ...
  • Clinical characteristics and outcomes of COVID-19 in patients with type 
    Sonmez, A; Demirci, I; Haymana, C; Tasci, I; Dagdelen, S; Salman, S; Ata, N; Sahin, I; Emral, R; Cakal, E; Atmaca, A; Sahin, M; Celik, O; Demir, T; Ertugrul, D; Unluturk, U; Caglayan, M; Satman, I (2021)
    Background Coronavirus disease 2019 (COVID-19) has been reported to be associated with a more severe course in patients with type 2 diabetes mellitus (T2DM). However, severe adverse outcomes are not recorded in all patients. ...
  • Lower COVID-19 Mortality in Patients with Type 2 Diabetes Mellitus 
    Emral, R; Haymana, C; Demirci, I; Tasci, I; Sahin, M; Cakal, E; Ata, N; Unluturk, U; Demir, T; Ertugrul, D; Sahi, I; Atmaca, A; Celik, O; Caglayan, M; Arga, KY; Dagdelen, S; Salman, S; Satman, I; Sonmez, A (2021)
    Introduction To investigate the effect of preexisting treatment with dipeptidyl peptidase-4 inhibitors (DPP-4is) on COVID-19-related hospitalization and mortality in patients with type 2 diabetes mellitus (T2DM). Methods ...
  • Lower COVID-19 Mortality in Patients with Type 2 Diabetes Mellitus 
    Emral, R; Haymana, C; Demirci, I; Tasci, I; Sahin, M; Cakal, E; Ata, N; Unluturk, U; Demir, T; Ertugrul, D; Sahin, I; Atmaca, A; Celik, O; Caglayan, M; Arga, KY; Dagdelen, S; Salman, S; Satman, I; Sonmez, A (2021)
  • Unexpectedly lower mortality rates in COVID-19 patients with and without 
    Satman, I; Demirci, I; Haymana, C; Tasci, I; Salman, S; Ata, N; Dagdelen, S; Sahin, I; Emral, R; Cakal, E; Atmaca, A; Sahin, M; Celik, O; Demir, T; Ertugrul, D; Unluturk, U; Arga, KY; Caglayan, M; Sonmez, A (2021)
    Aims: Type 2 diabetes mellitus (T2DM) is a risk factor for severe COVID-19. Our aim was to compare the clinical outcomes of patients with and without T2DM during the first hit of COVID-19 in Istanbul.& nbsp; Methods: A ...
  • The clinical outcomes of COVID-19 infection in patients with a history 
    Sahin, M; Haymana, C; Demirci, I; Tasci, I; Rifat, E; Unluturk, U; Satman, I; Demir, T; Cakal, E; Ata, N; Ertugrul, D; Salman, S; Sahin, I; Dagdelen, S; Celik, O; Caglayan, M; Atmaca, A; Sonmez, A (2021)
    Background There are scarce published data in differentiated thyroid cancer patients about new coronavirus disease 2019 (COVID-19) disease outcomes and mortality. Here, we evaluated COVID-19 infection outcomes and mortality ...
  • Unexpectedly lower mortality rates in COVID-19 patients with and without 
    Satman, I; Demirci, I; Haymana, C; Tasci, I; Salman, S; Ata, N; Dagdelen, S; Sahin, I; Emral, R; Cakal, E; Atmaca, A; Sahin, M; Celik, O; Demir, T; Ertugrul, D; Unluturk, U; Arga, KY; Caglayan, M; Sonmez, A (2021)
    Aims: Type 2 diabetes mellitus (T2DM) is a risk factor for severe COVID-19. Our aim was to compare the clinical outcomes of patients with and without T2DM during the first hit of COVID-19 in Istanbul.& nbsp; Methods: A ...
  • Lower COVID-19 Mortality in Patients with Type 2 Diabetes Mellitus 
    Emral, R; Haymana, C; Demirci, I; Tasci, I; Sahin, M; Cakal, E; Ata, N; Unluturk, U; Demir, T; Ertugrul, D; Sahi, I; Atmaca, A; Celik, O; Caglayan, M; Arga, KY; Dagdelen, S; Salman, S; Satman, I; Sonmez, A (2021)
    Introduction To investigate the effect of preexisting treatment with dipeptidyl peptidase-4 inhibitors (DPP-4is) on COVID-19-related hospitalization and mortality in patients with type 2 diabetes mellitus (T2DM). Methods ...
  • Lower COVID-19 Mortality in Patients with Type 2 Diabetes Mellitus 
    Emral, R; Haymana, C; Demirci, I; Tasci, I; Sahin, M; Cakal, E; Ata, N; Unluturk, U; Demir, T; Ertugrul, D; Sahin, I; Atmaca, A; Celik, O; Caglayan, M; Arga, KY; Dagdelen, S; Salman, S; Satman, I; Sonmez, A (2021)
  • Clinical characteristics and outcomes of COVID-19 in patients with type 
    Sonmez, A; Demirci, I; Haymana, C; Tasci, I; Dagdelen, S; Salman, S; Ata, N; Sahin, I; Emral, R; Cakal, E; Atmaca, A; Sahin, M; Celik, O; Demir, T; Ertugrul, D; Unluturk, U; Caglayan, M; Satman, I (2021)
    Background Coronavirus disease 2019 (COVID-19) has been reported to be associated with a more severe course in patients with type 2 diabetes mellitus (T2DM). However, severe adverse outcomes are not recorded in all patients. ...
  • The clinical outcomes of COVID-19 infection in patients with a history 
    Sahin, M; Haymana, C; Demirci, I; Tasci, I; Rifat, E; Unluturk, U; Satman, I; Demir, T; Cakal, E; Ata, N; Ertugrul, D; Salman, S; Sahin, I; Dagdelen, S; Celik, O; Caglayan, M; Atmaca, A; Sonmez, A (2021)
    Background There are scarce published data in differentiated thyroid cancer patients about new coronavirus disease 2019 (COVID-19) disease outcomes and mortality. Here, we evaluated COVID-19 infection outcomes and mortality ...
  • Clinical outcomes of non-diabetic COVID-19 patients with different blood 
    Haymana, C; Demirci, I; Tasci, I; Cakal, E; Salman, S; Ertugrul, D; Ata, N; Unluturk, U; Dagdelen, S; Atmaca, A; Sahin, M; Celik, O; Demir, T; Emral, R; Sahin, I; Caglayan, M; Satman, I; Sonmez, A (2021)
    Purpose New coronavirus disease 2019 (COVID-19) has a worse prognosis in patients with diabetes. However, there are insufficient data about the effect of hyperglycemia on COVID-19 prognosis in non-diabetic patients. This ...
  • Clinical Characteristics and Outcomes of COVID-19 Patients with 
    Sahin, I; Haymana, C; Demir, T; Demirci, I; Tasci, I; Atmaca, A; Cakal, E; Ata, N; Emral, R; Unluturk, U; Ertugrul, D; Salman, S; Sahin, M; Dagdelen, S; Celik, O; Caglayan, M; Satman, I; Sonmez, A (2022)
    Purpose While obesity is related to more severe outcomes of coronavirus disease 2019 (COVID-19), factors leading to poor prognosis still remain unclear. The present study evaluated the outcomes of COVID-19 patients who ...
  • No association of anti-osteoporosis drugs with COVID-19-related outcomes 
    Atmaca, A; Demirci, I; Haymana, C; Tasci, I; Sahin, I; Cakal, E; Ata, N; Dagdelen, S; Salman, S; Emral, R; Sahin, M; Celik, O; Demir, T; Ertugrul, D; Unluturk, U; Caglayan, M; Satman, I; Sonmez, A (2022)
    This study was performed to evaluate whether the use of drugs in the treatment of osteoporosis in women is associated with COVID-19 outcomes. The results showed that the risk of hospitalization, intensive care unit admission, ...
  • Higher rate of COVID-19 mortality in patients with type 1 than type 2 
    Demirci, I; Haymana, C; Tasci, I; Satman, I; Atmaca, A; Sahin, M; Ata, N; Unluturk, U; Cakal, E; Dagdelen, S; Sahin, I; Celik, O; Ertugrul, D; Demir, T; Emral, R; Caglayan, M; Salman, S; Birinci, S; Sonmez, A (2022)
    Introduction: COVID-19 disease has a worse prognosis in patients with diabetes, but comparative data about the course of COVID-19 in patients with type 1 (T1DM) and type 2 diabetes (T2DM) are lacking. The purpose of this ...
  • No association of Gaucher disease with COVID-19-related outcomes: a 
    Demirci, I; Demir, T; Dagdelen, S; Haymana, C; Tasci, I; Atmaca, A; Ertugrul, D; Ata, N; Sahin, M; Salman, S; Sahin, I; Emral, R; Unluturk, U; Cakal, E; Celik, O; Caglayan, M; Satman, I; Sonmez, A (2022)
    Background It is well documented that patients with chronic metabolic diseases, such as diabetes and obesity, are adversely affected by the COVID-19 pandemic. However, when the subject is rare metabolic diseases, there are ...
  • No association of anti-osteoporosis drugs with COVID-19-related outcomes 
    Atmaca, A; Demirci, I; Haymana, C; Tasci, I; Sahin, I; Cakal, E; Ata, N; Dagdelen, S; Salman, S; Emral, R; Sahin, M; Celik, O; Demir, T; Ertugrul, D; Unluturk, U; Caglayan, M; Satman, I; Sonmez, A (2022)
    This study was performed to evaluate whether the use of drugs in the treatment of osteoporosis in women is associated with COVID-19 outcomes. The results showed that the risk of hospitalization, intensive care unit admission, ...
  • Clinical Characteristics and Outcomes of COVID-19 Patients with 
    Sahin, I; Haymana, C; Demir, T; Demirci, I; Tasci, I; Atmaca, A; Cakal, E; Ata, N; Emral, R; Unluturk, U; Ertugrul, D; Salman, S; Sahin, M; Dagdelen, S; Celik, O; Caglayan, M; Satman, I; Sonmez, A (2022)
    Purpose While obesity is related to more severe outcomes of coronavirus disease 2019 (COVID-19), factors leading to poor prognosis still remain unclear. The present study evaluated the outcomes of COVID-19 patients who ...
  • No association of Gaucher disease with COVID-19-related outcomes: a 
    Demirci, I; Demir, T; Dagdelen, S; Haymana, C; Tasci, I; Atmaca, A; Ertugrul, D; Ata, N; Sahin, M; Salman, S; Sahin, I; Emral, R; Unluturk, U; Cakal, E; Celik, O; Caglayan, M; Satman, I; Sonmez, A (2022)
    Background It is well documented that patients with chronic metabolic diseases, such as diabetes and obesity, are adversely affected by the COVID-19 pandemic. However, when the subject is rare metabolic diseases, there are ...